Related Experiment Video

Updated: Aug 6, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers

Bratislav Janjic1, Pedro Andrade, Xiao-Fei Wang

  • 1Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

Journal of Immunology (Baltimore, Md. : 1950)
|August 5, 2006
PubMed

Insights

Cancer germline antigen TRAG-3 elicits spontaneous CD4+ T cell responses in patients with advanced melanoma and breast cancer. These responses target a single immunodominant epitope, independent of antibody production, offering potential for cancer vaccine development.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • The taxol resistance gene TRAG-3 is a cancer germline antigen found in various tumors, including melanoma, breast, and lung cancers.
  • Understanding immune responses to cancer antigens is crucial for developing effective immunotherapies.

Purpose of the Study:

  • To investigate spontaneous T cell responses against the TRAG-3 antigen in patients with advanced cancers.
  • To characterize the immunodominant epitopes and immune profiles associated with TRAG-3 expression.

Main Methods:

  • Isolation and characterization of TRAG-3-specific CD4+ T cells and clones.
  • In vitro expansion and functional assays of T cells.
  • Analysis of T cell receptor (TCR) beta gene usage.
  • Detection of antibody responses against TRAG-3.

Main Results:

  • Patients with stage IV melanoma and breast cancer showed spontaneous CD4+ T cell responses against a single immunodominant TRAG-3 peptide epitope.
  • TRAG-3-specific CD4+ T cells recognized peptide-pulsed antigen-presenting cells and TRAG-3 protein-loaded dendritic cells.
  • All stage IV melanoma patients with TRAG-3-expressing tumors had these T cell responses, but no detectable IgG antibody responses.
  • TCR beta gene usage suggested a restricted repertoire in patients with TRAG-3-expressing tumors.

Conclusions:

  • Spontaneous immune responses against cancer germline antigen TRAG-3 involve CD4+ T cells targeting a single immunodominant epitope, independent of antibody responses.
  • The immunodominant TRAG-3(34-48) peptide is a key target for monitoring immune responses and developing cancer vaccines.
  • TRAG-3 represents a promising target for novel immunotherapeutic strategies in TRAG-3-expressing cancers.

More Related Videos

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...